The role of patient financial assistance programs in reducing costs for cancer patients

Journal of Managed Care and Specialty Pharmacy

Volumn 23, Issue 4, 2017, Pages 407-411

  Zullig, Leah L ^a   Wolf, Steven ^b   Vlastelica, Lisa ^b   Shankaran, Veena ^a   Yousuf Zafar, S ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Biostatistics and Bioinformatics ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ENZALUTAMIDE; LETROZOLE; TAMOXIFEN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CENTER; CANCER PATIENT; CLINICAL EVALUATION; CLINICAL PHARMACY; CONTROLLED STUDY; DRUG COST; FINANCIAL ASSISTANCE PROGRAM; FINANCIAL MANAGEMENT; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; PATIENT ATTITUDE; PRESCRIPTION; RETROSPECTIVE STUDY; COST CONTROL; ECONOMICS; MEDICAL CARE; NEOPLASMS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTINEOPLASTIC AGENTS; COST CONTROL; DRUG COSTS; DRUG PRESCRIPTIONS; HUMANS; INSURANCE, HEALTH; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAL ASSISTANCE; NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85016333631     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2017.23.4.407     Document Type: Article

References (20)

1. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):S1-14.
2. Schott S, Schneeweiss A, Reinhardt J, et al. Acceptance of oral chemotherapy in breast cancer patients -a survey study. BMC Cancer. 2011;11:129.
3. Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354-76.
4. Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33(19):2190-96.
5. Bennette CS, Richards C, Sullivan SD, Ramsey SD. Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff(Millwood). 2016;35(5):805-12.
6. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-11.
7. Bestvina CM, Zullig LL, Yousuf Zafar S. The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol. 2014;10(14):2189-99.
8. Nipp RD, Zullig LL, Samsa G, et al. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. Psychooncology. 2016;25(6):719-25.
9. Ramsey S, Blough D, KirchhoffA, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff(Millwood). 2013;32(6):1143-52.
10. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980-86.
11. Kircher SM, Meeker CR, Nimeiri H, et al. The parity paradigm: can legislation help reduce the cost burden of oral anticancer medications? Value Health. 2016;19(1):88-98.
12. Howard DH. Drug companies' patient-assistance programs -helping patients or profits? New Engl J Med. 2014;371(2):97-99.
13. Felder TM, Palmer NR, Lal LS, Mullen PD. What is the evidence for pharmaceutical patient assistance programs? A systematic review. J Health Care Poor Underserved. 2011;22(1):24-49.
14. Chisholm MA, DiPiro JT. Pharmaceutical manufacturer assistance programs. Arch Intern Med. 2002;162(7):780-84.
15. Zafar Y, Asabere A, Bastian A. Oncology patient assistance programs (PAPs): A first-in-kind analysis of U.S. drug manufacturer program benefits and eligibility requirements. Eur J Cancer. 2015;51(Suppl 3):S176 [Abstract 1213]. Available at: http://www.ejcancer.com/article/S0959-8049(16)30517-2/abstract. Accessed February 25, 2017.
16. Ubel PA, Bach PB. Copay assistance for expensive drugs: a helping hand that raises costs. Ann Intern Med. 2016;165(12):878-79.
17. Choudhry NK, Lee JL, Agnew-Blais J, Corcoran C, Shrank WH. Drug company-sponsored patient assistance programs: a viable safety net? Health Aff(Millwood). 2009;28(3):827-34.
18. Felder TM, Bennett CL. Can patients afford to be adherent to expensive oral cancer drugs? Unintended consequences of pharmaceutical development. J Oncol Pract. 2013;9(6 Suppl):64s-66s. Available at: http://ascopubs. org/doi/pdf/10.1200/JOP.2013.001167. Accessed February 25, 2017.
19. Rutherford C. OIG Continues to refine guidance on patient assistance programs. The National Law Review. February 23, 2016. Available at: http://www.natlawreview.com/article/oig-continues-to-refine-guidance-patientassistance-programs. Accessed February 25, 2017.
20. Elgin B, Langreth R. How big pharma uses charity programs to cover for drug price hikes: a billion-dollar system in which charitable giving is profitable. BloombergBusinessweek. May 19, 2016. Available at: http://www. bloomberg.com/news/articles/2016-05-19/the-real-reason-big-pharmawants-to-help-pay-for-your-prescription. Accessed February 25, 2017.